PHILADELPHIA – Even small amounts of breastmilk strongly influences the accumulation of viral populations in the infant gut and provides a protective effect against potentially pathogenic viruses, according to researchers who examined hundreds of babies in a study from the Perelman School of Medicine at the University of Pennsylvania.
The findings expand upon prior research that suggests that breastfeeding plays a key role in the interaction between babies and the microbial environment. This latest research could influence strategies for the prevention of early gastrointestinal disorders, and encourage mothers to feed babies breastmilk even when mixed with formula. The findings are published in Nature.
Penn researchers measured the numbers and types of viruses in the first stool — meconium — and subsequent stools of newborns in the United States and Botswana using advanced genome sequencing and other methods. Upon delivery, babies had little or no colonization, but by one month of life populations of viruses and bacteria were well developed, with numbers of viruses reaching a billion per gram of gut contents. Most of the first wave of viruses turned out to be predators that grow in the first bacteria that colonize the infant gut. Later, at four months, viruses that can replicate in human cells and potentially make humans sick were more prominent in the babies’ stools. A strong protective effect was seen for breastfeeding, which suppressed the accumulation of these potentially pathogenic viruses. Similar results were seen for infants from the US and Botswana. Another conclusion from this work was that breastmilk could be protective even if sometimes mixed with formula, compared to a with formula-only diet.
“These findings can help us better understand why some babies get sick and develop life-threatening infections in their first months of life,” said senior author Frederic Bushman, PhD, chair of the department of Microbiology.
The newborns’ home country also played a part in the prevalence of viral infections. Babies from Botswana were more likely to have those potentially-harmful viruses in their stools at that 4-month mark compared to the stools of babies from the US.
“Location of the mom and baby seems to play a role, probably due to the kind and number of microorganisms babies are exposed to environmentally,” said first author Guanxiang Liang, PhD, a postdoctoral researcher in the department at Microbiology. “Nevertheless, Botswana-born babies still seemed to benefit from breastfeeding, whether exclusively or in addition to formula consumption.”
In the future, Bushman and Liang want to look at varying ages to see how development of the virome — the virus population in the gut — influences a child’s growth, how virome colonization varies in infants around the world, and how virome colonization influences outcomes in preterm birth.
Additional Penn authors include Scott Sherrill-Mix, Lyanna R. Kessler, Gary D. Wu, and Michal A. Elovitz.
The research was done in collaboration with the division of Gastroenterology, Hepatology, and Nutrition at Children’s Hospital of Philadelphia and the department of Paediatric and Adolescent Health, Faculty of Medicine of the University of Botswana.
Funding support for the study comes from the National Institutes of Health (R61-HL137063, R01-HL113252, R01DK107565, UL1TR000003, UL1TR001878, K23 AI135090), the Penn Center for AIDS Research (P30 AI 045008), the PennCHOP Microbiome Program, the Commonwealth Universal Research Enhancement (C.U.R.E) program (SAP # 4100068710), the American Beverage Foundation for a Healthy America, and the Duke Center for AIDS Research (5P30 AI064518).
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, excellence in patient care, and community service. The organization consists of the University of Pennsylvania Health System and Penn’s Raymond and Ruth Perelman School of Medicine, founded in 1765 as the nation’s first medical school.
The Perelman School of Medicine is consistently among the nation's top recipients of funding from the National Institutes of Health, with $550 million awarded in the 2022 fiscal year. Home to a proud history of “firsts” in medicine, Penn Medicine teams have pioneered discoveries and innovations that have shaped modern medicine, including recent breakthroughs such as CAR T cell therapy for cancer and the mRNA technology used in COVID-19 vaccines.
The University of Pennsylvania Health System’s patient care facilities stretch from the Susquehanna River in Pennsylvania to the New Jersey shore. These include the Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, Chester County Hospital, Lancaster General Health, Penn Medicine Princeton Health, and Pennsylvania Hospital—the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is an $11.1 billion enterprise powered by more than 49,000 talented faculty and staff.